Autism - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 156 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Autism - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Autism - Pipeline Review, H2 2014', provides an overview of the Autism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Autism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Autism Overview 10
Therapeutics Development 11
Pipeline Products for Autism - Overview 11
Pipeline Products for Autism - Comparative Analysis 12
Autism - Therapeutics under Development by Companies 13
Autism - Therapeutics under Investigation by Universities/Institutes 16
Autism - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Autism - Products under Development by Companies 21
Autism - Products under Investigation by Universities/Institutes 22
Autism - Companies Involved in Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Egenix, Inc. 25
Novartis AG 26
Merz Pharma GmbH & Co. KgaA 27
Mitsubishi Tanabe Pharma Corporation 28
Teva Pharmaceutical Industries Limited 29
BrainStorm Cell Therapeutics Inc. 30
Avanir Pharmaceuticals, Inc. 31
Curemark, LLC 32
Coronado Biosciences, Inc. 33
Omeros Corporation 34
Intra-Cellular Therapies, Inc. 35
Cellceutix Corporation 36
Heptares Therapeutics Ltd. 37
Edison Pharmaceuticals, Inc. 38
Otsuka Holdings Co., Ltd. 39
Reviva Pharmaceuticals Inc. 40
Naurex, Inc. 41
Mnemosyne Pharmaceuticals, Inc. 42
BioCrea GmbH 43
Saniona AB 44
Confluence Pharmaceuticals LLC 45
MedDay 46
Autism - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
CM-AT - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lurasidone hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
aripiprazole - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
fluoxetine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
memantine hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CNDO-201 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
oxytocin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
vatiquinone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RG-7314 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
fluoxetine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
fingolimod hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Stem Cell Therapy for Autism - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
glatiramer acetate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ITI-007 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Stem Cell Therapy for Central Nervous System Disorders, Genetic Disorders and Musculoskeletal Disorders - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
KM-391 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Antagonize mGluR5 for Autism, Depression and Dyskinesia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
CN-2097 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule to Target GPR63 for Autism - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
acamprosate calcium - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
suramin hexasodium - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
carbetocin - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecule to Modulate GABRA5 Receptor for Alzheimer's Disease, Schizophrenia and Autism - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Drug for Autism - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
NRX-20xx - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Drug to Agonize GABA Alpha 4 Delta Receptor for Autism and Sleep Disorders - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Drugs for Autism - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Small Molecules for Cancer and Autism - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Drug for Autism Spectrum Disorders - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Small Molecules to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
RP-5063 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
oxytocin - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
MD-1103 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Autism - Recent Pipeline Updates 116
Autism - Dormant Projects 147
Autism - Discontinued Products 148
Autism - Product Development Milestones 149
Featured News & Press Releases 149
Jun 26, 2014: Coronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder 149
May 14, 2014: Coronado Biosciences Initiates Phase 2a Clinical Study of TSO in Pediatric Patients With Autism Spectrum Disorder 149
Feb 14, 2014: New funding puts Rett Syndrome cure on the horizon 149
Dec 12, 2013: Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting 150
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 151
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 151
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 152
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 152
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 152
Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 153
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 15

List of Tables
Number of Products under Development for Autism, H2 2014 11
Number of Products under Development for Autism - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 24
Autism - Pipeline by Egenix, Inc., H2 2014 25
Autism - Pipeline by Novartis AG, H2 2014 26
Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 27
Autism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 28
Autism - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 29
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 30
Autism - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 31
Autism - Pipeline by Curemark, LLC, H2 2014 32
Autism - Pipeline by Coronado Biosciences, Inc., H2 2014 33
Autism - Pipeline by Omeros Corporation, H2 2014 34
Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 35
Autism - Pipeline by Cellceutix Corporation, H2 2014 36
Autism - Pipeline by Heptares Therapeutics Ltd., H2 2014 37
Autism - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 38
Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 39
Autism - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 40
Autism - Pipeline by Naurex, Inc., H2 2014 41
Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 42
Autism - Pipeline by BioCrea GmbH, H2 2014 43
Autism - Pipeline by Saniona AB, H2 2014 44
Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2014 45
Autism - Pipeline by MedDay, H2 2014 46
Assessment by Monotherapy Products, H2 2014 47
Assessment by Combination Products, H2 2014 48
Number of Products by Stage and Target, H2 2014 51
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 56
Number of Products by Stage and Molecule Type, H2 2014 58
Autism Therapeutics - Recent Pipeline Updates, H2 2014 116
Autism - Dormant Projects, H2 2014 147
Autism - Discontinued Products, H2 2014 148